Why it can take time and effort to find the right meds to help mental health

The Clancy Trial and the Long, Uncertain Road to the Right Psychiatric Drug

Earthguardiansonline.com – A jury in Ohio spent its first full day of deliberations weighing whether a 36-year-old labor and delivery nurse deserved criminal punishment for killing her three young children in 2023. At the center of the case was not only the question of intent and capacity, but a far more tangled issue: whether the dozens of psychiatric medications prescribed to Lindsay Clancy for depression, anxiety, and other conditions had been managed competently, or whether they had contributed to the psychotic episode that preceded the killings.

The day before Clancy strangled her children, cut her own wrists and throat, and leapt from a second-story window, she typed a short message into her phone. Prosecutors displayed that message to the jury during trial. It read:

“Medication stole my motherhood and my life.”

Her defense attorney, Kevin Riddington, argued in closing that Clancy was overmedicated and operating in a state of psychosis at the time of the killings, making her criminally irresponsible. He pointed to a rare diagnosis called postpartum psychosis, a condition that research links to elevated risks of both infanticide and suicide when it goes untreated.

“She was reaching out for help, and she was not getting it,” Riddington told the court, as Clancy nodded from the gallery.

Prosecutor Jennifer Sprague offered a sharply different reading. In her closing remarks she emphasized that the manner of the killings suggested premeditation, that Clancy understood the difference between right and wrong, that she had misled her mental health providers, and that she had failed to follow medication instructions.

“She knows, as a nurse, the importance of following the instructions of your medications,” Sprague said.

Since the trial, Clancy has filed suit against her treating physicians. The complaint alleges they failed to diagnose her properly and instead “subjected her to a disorganized, uncoordinated course of polypharmacy that exacerbated her condition and precipitated a severe psychotic break.” All of the named providers declined to comment while litigation is pending.

What the Trial Illuminates About Psychiatric Pharmacology

Dr. Joseph Goldberg, a psychiatrist and psychopharmacologist with no connection to the Clancy case, framed the proceedings as a public reminder of how layered and difficult the treatment of severe mental illness truly is.

“It has been an opportunity to remind us all about the complexities of severe mental illness and the complexities of treating mental illness,” Goldberg said.

That complexity is not abstract. In the United States, medication remains the single most common intervention for mental health conditions. The Centers for Disease Control and Prevention estimates that nearly 20 percent of adults are currently taking at least one psychiatric drug. Yet identifying the correct agent, at the correct dose, for the correct patient, can take weeks or months of trial, adjustment, and close monitoring.

The Major Drug Categories and How They Work

Psychiatric medications generally fall into four or five broad classes, each targeting different neurochemical pathways.

Selective Serotonin Reuptake Inhibitors

The largest and most widely prescribed group includes SSRIs such as Celexa, Prozac, and Zoloft. These agents are first-line treatments for a spectrum of depressive and anxiety disorders. Their mechanism is straightforward in outline: they block the rapid reuptake of serotonin by presynaptic neurons, allowing the neurotransmitter to remain active in the synaptic cleft for a longer period. Over time, the brain compensates by desensitizing certain serotonin receptors. That downstream adjustment triggers the release of brain-derived neurotrophic factor, a protein that functions somewhat like fertilizer for neural tissue, encouraging the growth of new neurons and synaptic connections and gradually lifting mood.

Because of that slow neuroplastic cascade, SSRIs typically require four to eight weeks before a patient notices meaningful benefit. Common early side effects—nausea, diminished libido, mild headaches—often attenuate as the body adapts. An exception exists for menstrual-related mood disorders, where the hormonal milieu of the brain can accelerate the therapeutic onset.

Norepinephrine-Dopamine and Serotonin-Norepinephrine Reuptake Inhibitors

When serotonin-targeted therapy proves insufficient, clinicians may turn to agents that modulate other neurotransmitter systems. Norepinephrine-dopamine reuptake inhibitors, exemplified by bupropion, block the reabsorption of norepinephrine and dopamine, two chemicals implicated in stress response, reward processing, alertness, and sustained attention. Serotonin-norepinephrine reuptake inhibitors—Cymbalta, Fetzima, and Effexor XR among them—simultaneously prolong the activity of serotonin and norepinephrine, shaping the body’s fight-or-flight circuitry alongside mood regulation.

Benzodiazepines and the Short-Term Window

For acute episodes of extreme worry, panic, social anxiety, or terror, benzodiazepines such as Ativan, Librium, Xanax, and Valium can produce rapid relief by enhancing inhibitory signaling in the nervous system. Their speed is precisely why they are usually reserved for brief courses: dependence develops quickly, and if the nervous system’s excitatory activity is suppressed too far, dangerous side effects including respiratory depression and profound sedation can emerge.

Why Switching Medications Is Never Simple

The Clancy case underscores a reality that many patients encounter: finding the right drug, or the right combination, is rarely a single decision. It involves weeks of observation, dose titration, monitoring for adverse effects, and frequent communication between patient and prescriber. A medication that appears ineffective at week three may simply not yet have completed its neuroplastic work. Conversely, a regimen that stacks multiple agents without clear therapeutic logic—what lawyers call “polypharmacy”—can worsen the very symptoms it was meant to relieve.

For the roughly one in five American adults managing a mental health condition with medication, the trial’s central lesson is both sobering and practical: the path from prescription to relief is long, individualized, and demands sustained partnership with a clinician who understands the pharmacology, the patient’s history, and the narrow margins between therapeutic benefit and iatrogenic harm.